1. Home
  2. APLT vs CELU Comparison

APLT vs CELU Comparison

Compare APLT & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • CELU
  • Stock Information
  • Founded
  • APLT 2016
  • CELU 2016
  • Country
  • APLT United States
  • CELU United States
  • Employees
  • APLT N/A
  • CELU N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • CELU Biotechnology: Pharmaceutical Preparations
  • Sector
  • APLT Health Care
  • CELU Health Care
  • Exchange
  • APLT Nasdaq
  • CELU Nasdaq
  • Market Cap
  • APLT 59.2M
  • CELU 64.3M
  • IPO Year
  • APLT 2019
  • CELU N/A
  • Fundamental
  • Price
  • APLT $0.44
  • CELU $2.18
  • Analyst Decision
  • APLT Buy
  • CELU Strong Buy
  • Analyst Count
  • APLT 5
  • CELU 1
  • Target Price
  • APLT $4.13
  • CELU $6.00
  • AVG Volume (30 Days)
  • APLT 718.5K
  • CELU 147.7K
  • Earning Date
  • APLT 11-06-2025
  • CELU 08-29-2025
  • Dividend Yield
  • APLT N/A
  • CELU N/A
  • EPS Growth
  • APLT N/A
  • CELU N/A
  • EPS
  • APLT N/A
  • CELU N/A
  • Revenue
  • APLT $121,000.00
  • CELU $44,590,000.00
  • Revenue This Year
  • APLT N/A
  • CELU N/A
  • Revenue Next Year
  • APLT $5,931.24
  • CELU $76.00
  • P/E Ratio
  • APLT N/A
  • CELU N/A
  • Revenue Growth
  • APLT N/A
  • CELU 4.45
  • 52 Week Low
  • APLT $0.30
  • CELU $1.00
  • 52 Week High
  • APLT $10.62
  • CELU $5.22
  • Technical
  • Relative Strength Index (RSI)
  • APLT 45.85
  • CELU 35.15
  • Support Level
  • APLT $0.40
  • CELU $2.05
  • Resistance Level
  • APLT $0.46
  • CELU $2.41
  • Average True Range (ATR)
  • APLT 0.03
  • CELU 0.28
  • MACD
  • APLT -0.01
  • CELU -0.06
  • Stochastic Oscillator
  • APLT 27.67
  • CELU 11.46

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: